Based on the evidence that sorafenib as post-transplant maintenance therapy for FLT3-mutated AML can improve relapse-free survival and demonstrate good tolerability, the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) recommends using sorafenib to optimize long-term disease control. The gene discussed is FLT3; the disease is acute myeloid leukemia.